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Immune and inflammatory responses mediated by cytokines are essential in the pathophysiology of asthma. The
aim of this study was to analyse the cytokine mRNA profiles in bronchoalveolar lavage (BAL) cells of patients with
mild atopic asthma, before and after induction of a subclinical allergic airway inflammation. For this purpose, eight
patients with mild atopic asthma received low-dose allergen inhalations equivalent to 10% of a provocational dose
causing a 20% fall in forced expiratory flow in 1 sec (PD20) for 7 weekdays. BAL was performed before and after
low-dose provocations in patients, and without provocation in five healthy controls. Alveolar macrophages (AM)
were enriched by negative selection, using magnetic beads, to enable separate studies of the BAL cells. Using a
semiquantitative RT-PCR technique, the mRNA expression of macrophage-derived cytokines interleukin (IL)-1,
IL-6, IL-8, IL-10, IL-12, IL-13, interferon (IFN)-g, tumour necrosis factor (TNF)-a and transforming growth
factor (TGF)-b was analysed. After low-dose provocations, we observed a significant increase in the expression of
IL-13 mRNA (P=001) in BAL cells enriched for AM of the asthmatic patients. The increased IL-13 mRNA
positively correlated with the proportion of BAL fluid eosinophils (r=07, P=005). Moreover, a tendency was
found towards an increased IL-1 and a reduced IL-6, IL-8, IFN-g and TNF-a expression by the BAL cells.
Comparing asthmatic patients before low-dose provocations and healthy controls, a significantly higher expression
of IL-6 (P50003), IL-10 (P50005) and TGF-b (P50003) and a significantly lower expression of IL-8 (P50005)
and TNF-a (P5001) was detected in the patients. In summary, repeated low-dose allergen provocations of
asthmatic patients results in a modified BAL cell cytokine mRNA profile with increased production of IL-13, that
may be of importance for the development of a Th2-like immune response. A possible source of the increased IL-13
mRNA is AM, which may have a more active function in the allergic inflammation than previously thought.
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Bronchial asthma is a chronic inflammatory disease of the
airways, influenced by genetic and environmental factors,
and characterized by bronchial hyperreactivity, eosinophil
infiltration, elevated serum IgE levels and excessive airway
mucus production (1). Bronchial inflammation reflects aReceived 13 December 1999 and accepted in revised from 15 March
2000.
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0954-6111/00/080806+09 $35?00/0cell-mediated immune process, in which cytokine produc-
tion by activated T cells may orchestrate the immune
response. Thus, the pathology of asthma is thought to be
mediated primarily by the type 2 cytokines IL-4, IL-5 and
IL-13 (2,3).
In animal models, IL-13 has been recently implicated in
allergic asthma, acute lung inflammatory injury and
pulmonary granuloma formation (4–7). IL-13 shares
receptor components and biological properties with IL-4
such as induction of IgE synthesis and downregulation of
IL-12 and IFN-g production, thereby favouring a type 2
cytokine response (8,9)
Repeated low-dose allergen exposure is a good method
for studying the development of allergic inflammation in
asthma. This model has been shown to provide a realistic# 2000 HARCOURT PUBLISHERS LTD
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eosinophilia and increased IL-5 in induced sputum,
associated with airway hyperresponsiveness without devel-
opment of marked acute bronchoconstriction (10–12). In a
recent study, we described an increased responsiveness to
methacholine and airway inflammation after repeated low-
dose allergen provocations in a group of patients with mild
asthma (13). In the present report, we used the same group
of patients to analyse the mRNA cytokine expression in
BAL cells enriched for alveolar macrophages (AM). We
found a significant increase in the expression of IL-13
mRNA, and a trend towards a reduced expression of the
pro-inflammatory cytokines IL-6 and IL-8 and of the Th1
associated cytokines IFN-g and TNF-a. Our results are in
line with the notion that a repeated exposure for low doses
of allergen elicits a Th2 deviated immune response, and
suggest the low-dose allergen provocation model to be
appropriate for studies of early inflammatory events in
allergic asthma.
Materials and methods
SUBJECTS
Eight patients with atopic asthma, seven females and one
male, with a median age of 29 years (range 24–41 years)
were included in the study. The patients had a history of
mild allergic asthma to pollen and/or to animal dander with
a positive skin prick test and positive radioallergoabsorbent
test (RAST, Pharmacia, Uppsala, Sweden). All patients
were in a stable phase of the disease with a median forced
expiratory volume in 1 sec (FEV1) 93% of the predicted
normal value (range 80–101%) and median total IgE values
of 79 kU l71 (range 25–170 kU l71). [For individual data
see Lensmar et al. (13).] No medication was taken except
for occasional b2-agonists. All patients were free from
symptoms of airway infection for at least 4 weeks prior to
the study. The study was performed outside the pollen
season and patients allergic to animal dander did not have
pets, and were asked to avoid animal contact during the
study period. Five healthy subjects (two females) without
symptoms or a history of allergy, with a median age of 25
years (range 23–27 years) were selected as controls. The
local Ethics Committee approved the study, and all patients
gave informed consent.
STUDY DESIGN
A first bronchoscopy with BAL was performed 2–3 weeks
before starting the allergen provocation. Basal FEV1 was
measured before the first dose of allergen as well as before
and 15 min after each allergen inhalation. Allergen doses of
birch or grass pollen (Aquagen, ALK, Copenhagen, Den-
mark) were selected according to previously determined
PD20 (the allergen dose causing 20% fall in FEV1).
Inhalation doses of allergen corresponding to 10% of
PD20 were administrated in the mornings, and at the same
time daily during 7 weekdays [see Lensmar et al. (13) for
more details]. The same dose was given every day andvaried from 84 SQ (arbitrary units related to the
concentration of the allergen) to 243 SQ between the
individuals. A second BAL was performed 1 day after
completed allergen provocation. All bronchial provocations
were performed by using a dosimeter controlled jet
nebulized Spira Electro 2 (Respiratory Care Center,
Hameenlinna, Finland). BAL was performed once in the
Control group without any preceding provocation.
BAL AND AM PREPARATION
BAL was performed using a flexible fibre-optic broncho-
scope (Olympus BF Type P20; Olympus Optical Co. Ltd,
Tokyo, Japan) as previously described (14). Briefly, the
patients were pre-medicated with Morphine–Scopolamine
(Pharmacia and Upjohn, Uppsula, Sweden) and adminis-
tered inhaled b2-agonist 10 min before the bronchoscopy.
The right middle lobe was instilled with five aliquots of 50
ml sterile buered saline solution (PBS), and the fluid was
gently aspirated after each aliquot, collected in a sterile
siliconized bottle and kept on ice. The lavage fluid was
filtered through a single layer of dacron net (type AP32,
Millipore, Bedford, Ireland) and centrifuged at 400 g for
10 min at 4oC. The cell pellet was resuspended in RMPI
1640 (Sigma-Aldrich Co, St Louis, MO, U.S.A.), counted
in a Bu¨rker chamber and the viability assessed by cellular
exclusion of trypan blue. Cytospin preparation was
performed by centrifugation of 66104 cells at 500 g for
3 min (Cytospin 2, Shandon Southern Instruments, Run-
corn, U.K.). One slide was stained in May–Gru¨nwald
Giemsa for evaluation of cell dierentials, and another in
Toluidine blue for assessment of metachromatic cell counts.
AM from BAL were enriched by negative selection using
anti-CD2 coated magnetic beads (Dynalbeads, Dynal,
Oslo, Norway) according to the manufacturer instructions,
resulting in a depletion of T-lymphocytes and natural killer
(NK) cells. The purity of this population was determined by
May–Gru¨nwald Giemsa and Toluidine blue stainings.
RNA EXTRACTION, cDNA SYNTHESIS
AND RT-PCR
Total cellular RNA was extracted from 1–26106 enriched
AM with RNAzolB (Biotecx Labs, Houston, TX, U.S.A.)
according to the manufacturer’s instructions. The RNA
was quantitated by spectrophotometry at 260 nm and
stored at 7708 C. The integrity of the RNA sample was
assessed by electrophoresis in a 16% agarose gel (BRL,
Gaithersburg, MD, U.S.A.) with 02 mgml71 ethidium
bromide.
RNA was denatured at 908 C for 5 min and chilled on
ice. First strand cDNA synthesis was performed in a final
volume of 20ml containing: 10ml of denatured RNA (1–5 mg),
4 ml buer (56, BRL), 15 ml dithiothretiol (100 mM, BRL),
2 ml dNTP (dATP, dCTP, dGTP and dTTP, 5mM each,
Pharmacia, Uppsala, Sweden), 05 ml RNasin (40U ml,
Promega, Madison, W), 10 ml random hexamer primers
pd(N)6 (1 mM, Pharmacia) and 10 ml reverse trancriptase
from murine Moloney leukemia virus (200 U ml71, BRL).
808 J. PRIETO ET AL.The samples were incubated at 408C for 45 min and then
heated for 5 min at 958C.
The cDNA was amplified by PCR in a 20 ml reaction
mixture containing 2 ml of the target cDNA, 025 mM
primers, 2 mM MgCl2, 02 mM dNTPs, 0025 Uml71 Taq
polymerase (Sigma) using a GeneAmp PCR System 9600
(Perkin Elmer, Norwalk, CT, U.S.A.). An appropriate
dilution of the cDNA samples and the number of cycles for
each primer were chosen after preliminary experiments,
ensuring that the samples remained within the exponential
range of amplification (data not shown). The housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
was used to check the quality of the cDNA preparation as
well to normalize the cDNA concentrations. The expression
of each cytokine was calculated in relation to G3PDH
expression. The cytokines and primer sequences used are
shown in Table 1.
PCR was conducted for 30–40 cycles under the following
conditions: denaturation at 948C, annealing at 628C for
cytokines (558C for G3PDH), and extension at 728C. IL-1,
IL-6, IL-10, IL-12, IL-13 and TNF-a primers were
synthesized on a DNA Synthesizer (Applied Biosystem,
Foster City, CA, U.S.A.) while IL-8, IFN-g, TGF-b and
G3PDH primers were purchased from Clontech (Palo Alto,
CA, U.S.A.). Phytohaemagglutinin stimulated mononuc-
lear cells expressed all cytokines tested for, and thus served
as a positive control to ascertain that each primer yielded a
PCR product of the correct size (data not shown). The PCR
products were visualized on a 16% agarose gel containing
02 mgml71 ethidium bromide, and analysed using a DC120TABLE 1. Cytokine list and oligonucleotide sequences for primer
Cytokine Primer sequence
5’–3’
IL-1 s GCCAATGACTCAGAGGA
IL-1 as TCTCAGGCATCTCCTTCA
IL-6 s TGAACTCCTTCTCCACAA
IL-6 as ATCCAGATTGGAAGCAT
IL-8 s ATGACTTCCAAGCTGGCC
IL-8 as TCTCAGCCCTCTTCAAAA
IL-10 s ACCAAGACCCAGACATC
IL-10 as GAGGTACAATAAGGTTT
IL-12p40 s CAGCAGTTGGTCATCTCT
IL-12p40 as CCAGCAGGTGAAACGTC
IL-13 s TGTTGACCACGGTCATTG
IL-13 as ATGTAAGAGCAGGTCCT
IFN-g s GCATCGTTTTGGGTTCTC
IFN-g as CTCCTTTTTCGCTTCCCTG
TNF-a s TGAGCACTGAAAGCATG
TNF-a as TTATCTCTCAGCTCCACG
TGF-b; s GCCCTGGACACCAACTA
TGF-b as AGGCTCCAAATGTAGGG
G3PDH s TGAAGGTCGGAGTCAAC
G3PDH as CATGTGGGCCATGAGGT
IL-13 probe TCTGGTTCTCGGTGATGT
s: sense; as: antisenseZoom Digital Camera connected to ID Image Analysis
Software (Kodak, Eastman Kodak Co. Rochester, NY,
U.S.A.). The relative mRNA levels were expressed as the
ratio of the net intensity detected in a given cytokine band
divided by that of its respective G3PDH band. The
specificity of amplified PCR products for G3PDH and
IL-13 was confirmed by Southern blot and hybridization
with 32P-labelled specific probes, according to standard
protocols. Radioactive products were scanned and analysed
in a Phosphoimager (Molecular Dynamics, U.S.A.).
STATISTICAL ANALYSIS
The Mann–Whitney U-test and the Wilcoxon matched
pairs test were used for intergroup and intragroup
comparisons, respectively. Correlations were calculated
using Spearman rank correlation test. A P-value of less
than 005 was considered statistically significant.
Results
PATIENTS AND BAL SAMPLES
After 7 weekdays of repeated low dose allergen provoca-
tions, an allergic inflammatory reaction, subclinical in six
out of eight asthmatic subjects, was observed as determined
by increased airway methacholine reactivity, increased BAL
fluid total cell and eosinophil counts and increased serum
eosinophilic cationic protein (ECP) levels. Detailed data ares and probe
PCR product
size (bp)
AGA 328
GC
GC 315
CCA
GTGGCT 289
ACTTCTC
AAG 352
CTCAAG
TG 420
CA
CT 353
TTAC
TTGGCTGTTACTGC 427
TTTTAGCTGCTGG
ATC 363
CC
TTGCT 161
GCAGG
GGATTTGGT 983
CCACCAC
FIG. 1. Analysis of interleukin (IL)-13 mRNA in
bronchoalveolar lavage (BAL) cells enriched for alveolar
macrophages (AM) obtained from mild asthmatic
patients before and after low-dose allergen provocation.
(a) PCR amplified products of IL-13 and G3PDH from
patients 1–8, analysed in 16% agarose gel containing 02
mg ml71 ethidium bromide. (b) Ratio of IL-13/G3PDH
mRNA net intensity obtained by Digital Image Analysis
Software of the PCR products showed in (a). (c) Southern
blot of IL-13 amplified products from patients 2, 5 and 6
and hybridized with 32P 5’-end-labelled IL-13 specific
probe.
(B) before and (A) after low-dose allergen provocation; 1-8:
patient numbers.
REPEATED LOW-DOSE ALLERGEN PROVOCATIONS 809presented in Lensmar et al. (13). To be able to perform
other studies in parallel with the detection of cytokine
mRNA following allergen provocation, BAL cells were
enriched for AM, resulting in a purity of 97% macro-
phages, as assessed by May–Gru¨nwald Giemsa and
Toluidine blue stainings. Contaminating cells in the enriched
AM fraction were (mean values) lymphocytes 15%,
neutrophils 10%, eosinophils 05% and a small number of
mast cells (23 in 10 visual fields, magnification 616).
CYTOKINE mRNA EXPRESSION BEFORE
AND AFTER LOW-DOSE ALLERGEN
A semiquantitative RT-PCR was performed to analyse
cytokine mRNA expression, using mRNA of the house-
keeping gene G3PDH to enable comparisons of each
cytokine mRNA transcript expression in BAL samples
before and after provocation [Fig. 1(a)]. The expression of
IL-13 mRNA was found to be statistically significantly
enhanced (P=001). IL-13 transcripts were detected only in
two out of the eight asthmatics (2/8) before provocation
and were found to be upregulated in all eight patients after
provocation [Fig. 1(a and b)]. In three of the patients, the
specificity for IL-13 on the amplified PCR material was
investigated and confirmed by probing transferred products
with an IL-13 probe complementary to sequences internal
to the primers [Fig. 1(c)]. A tendency was observed to a
reduced mRNA expression for IFN-g (7/8), IL-6 (6/8), IL-8
(6/8) and TNF-a (5/8) and to an increased expression of
mRNA for IL-1 (5/8) after the allergen provocations (Fig. 2).
Finally, IL-10, IL-12 and TGFb mRNA were detected but
without any distinct patterns before or after provocation.
The post-challenge increase in the expression of IL-13
showed a positive correlation with the increased BAL fluid
proportion of eosinophils (P=005, r=07), (Fig. 4) and
with the serum ECP values (P=009, r=07), although a
significant P-value was obtained only with the former
parameter. A significant positive correlation was also found
between the post-challenge change in BAL cell concentra-
tion and proportion of neutrophils and the change in IL-8
mRNA expression (P=0002, r=09 and P=001, r=08,
respectively).
CYTOKINE mRNA EXPRESSION IN
PATIENTS VERSUS HEALTHY CONTROLS
A significantly higher mRNA expression for IL-6
(P=0003), IL-10 (P=0005) and TGF-b (P=0003) was
found in patients (before allergen provocation) vs. controls
[Fig. 3(a)], while IL-8 (P=0003) and TNF-a (P=0008)
mRNA transcripts were significantly lower in the former
group [Fig 3(b)]. The same pattern of cytokine expression
was observed when comparing the asthmatics after
provocation with healthy controls, except for IL-13 that
was significantly higher (P=0005) expressed in asthmatics
than in controls but only after low-dose allergen provoca-
tion. No significant dierences were observed in the mRNAexpression of IL-1, IL-12, IL-13 and IFN-g cytokines
between the two groups.
Discussion
Low-dose allergen provocation has proven to be a useful
model for studying airway hyperresponsiveness as well as
the inflammatory process underlying mild bronchial asthma
(10–12). Recently, we demonstrated a subclinical inflam-
matory reaction after low-dose provocation in a group of
mild atopic asthmatic patients (13). In the present study,
FIG. 2. PCR analysis of interferon (IFN)-g, interleukin (IL)-6, IL-8, tumour necrosis factor (TNF)-a and IL-1 mRNA in
BAL cells enriched for alveolar macrophages (AM) obtained from mild asthmatic patients before and after low-dose
allergen provation. Data are presented as a ratio of cytokine/G3PDH mRNA net intensity obtained by Digital Image
Analysis Software (Kodak, Eastman Kodak Co., Rochester, NY, U.S.A.). (b) Before and (a) after low-dose allergen
provocation; 1-8: patient numbers.
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FIG 3. PCR analysis of interleukin (IL)-6, IL-8, IL-10, tumour necrosis factor (TNF)- and transforming growth factor
(TGF)- mRNA in bronchoalveolar lavage (BAL) cells enriched for AM obtained from mild asthmatic patients and healthy
control subjects. (a) Cytokines expressed at higher levels; and (b) lower level, in mild asthmatic patients compared with
healthy controls. Data are presented as a ratio of cytokine/G3PDH mRNA net intensity obtained by Digital Image Analysis
Software. (B) before low-dose allergen provocation (n=8); (C) controls (n=5). *P5001 and **P50005.
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FIG 4. Correlation changes in interleukin (IL)-13 mRNA
expression and the bronchoalveolar lavage (BAL) fluid
eosinophils proportion after low-dose allergen
provocations. P=005, R=07.
812 J. PRIETO ET AL.the same group of patients was analysed for cytokine
expression in BAL cells by using a semiquantitative RT-
PCR technique. Following 7 weekdays of repeated low-
dose allergen provocations, we found a significantly
increased IL-13 mRNA expression accompanied by in-
creased IL-1 but reduced IL-6, IL-8, IFN-g and TNF-a
mRNA expressions, in BAL cells enriched for AM.
The enhanced in vitro production of immunoglobulin E
(IgE) observed in asthmatic patients has been reported to
be mediated by IL-13, and therefore IL-13 may play a
central role in the pathogenesis of IgE-mediated allergic
diseases (15,16). The upregulation of IL-13 transcripts in
BAL cells of patients with mild asthma after low-dose
allergen provocations, as reported here, is in good
agreement with the recently demonstrated elevated expres-
sion of IL-13 mRNA in the bronchial mucosa of patients
with asthma (17). IL-13 selectively induces vascular cell
adhesion molecule (VCAM)-1 expression on endothelial
cells, favouring a VCAM-1/very late antigen (VLA)-4
dependent accumulation of inflammatory cells at the site
of the inflammatory reaction (18,19). Moreover, IL-13
enhances survival of eosinophils and may contribute to the
pathological activities of these cells in asthma (20). In line
with these reports, we found a positive correlation between
the post-challenge increase in the proportion of eosinophils
and the elevated IL-13 mRNA expression. Besides cell
infiltration, IL-13 may also be important for airway
obstruction (21), as shown by blocking or adding IL-13 in
experimental animal models (4,5).
In particular T lymphocytes, but also mast cells,
basophilic granulocytes and dendritic cells, are capable of
producing IL-13 (22–24). On the other hand, human
eosinophils are not considered as a source of IL-13 (25).
In our study, the vast majority (497 %) of BAL cells were
AM, which only recently were recognized as a potential
source of IL-13 (26). We found no correlation between the
numbers of contaminating cells and the increased IL-13
mRNA expression, and suggest that AM may be the source
of the elevated IL-13 mRNA expression following low-
dose allergen provocations. To confirm such an IL-13production by AM, one could apply in situ hybridization
techniques, something we were unable to perform in this
study due to lack of material.
Many biological activities of IL-13 are shared with IL-4,
probably due to the common IL4Ra chain for IL4R and
IL-13R, required for signal transduction (4,8,27). IL-13
may aect T cell functions and Th2-cell dierentiation
indirectly through its downregulatory eects on the
production of IL-12, IFN-g and TNF-a (9,28). This
observation is in agreement with the decreased expression
of IFN-g transcripts in our study. Although IFN-g
expression has previously been considered to be restricted
to T and NK cells, unstimulated or IL-12-stimulated AM as
well as AM from tuberculosis patients have been shown to
produce and secrete IFN-g (29,30). Also the downregula-
tion of the pro-inflammatory cytokines IL-6 and TNF-a
and the chemokine IL-8 after low-dose inhalations may be
due to the inhibitory capacity of IL-13 on the monocyte/
macrophage production of cytokines (6,8).
In the BAL cells of patients before allergen challenge vs.
controls, there was a significantly higher expression of the
Th2 associated cytokines IL-6 and IL-10, as well as of
TGF-b that has been implicated in airway wall remodelling
activity in asthma. In contrast, the cytokines IL-8 and
TNF-a were expressed at lower levels in asthmatics than in
controls. Our results are in line with previous reports
showing an increased expression of IL-10 mRNA in BAL
fluid from asthmatics, an inhibitory capacity of IL-10 on
macrophage cytokine production and increased levels of
TGF-b in BAL fluid from asthmatics (31–34).
In summary, the cytokine pattern in BAL cells from
patients with mild atopic asthma after repeated low-dose
allergen provocations is characterized by a significant IL-13
upregulation and an IFN-g downregulation in addition to
an inhibition of pro-inflammatory cytokine expression, i.e
in part a Th2 deviated immune response. Although the
origin of IL-13 was not firmly established in this study, AM
is a possible source as they made up 497 % of the
investigated cells. This could indicate that AM play a more
regulatory role in the pathogenesis of allergic asthma than
previously believed.
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